-

Hildred Capital Management Named to Inc.’s 2024 List of Founder-Friendly Investors

NEW YORK--(BUSINESS WIRE)--Hildred Capital Management (“Hildred”), a healthcare-focused private equity firm that seeks opportunities to create value in middle-market companies, today announced that it has been named to Inc.'s 2024 Founder-Friendly Investors list. The list honors investment firms that remain actively involved with the businesses in which they invest and that have earned the trust of the entrepreneurs they support.

On behalf of Hildred, Co-Founders and Managing Partners Andrew Goldman and David Solomon stated: “Our role as a reliable, hands-on partner to our portfolio of businesses and their management teams is woven into our DNA. We take this responsibility seriously and we are committed to their long-term success. We are proud to be recognized by Inc. as a founder-friendly investor and remain focused on building great companies and achieving exceptional financial returns on behalf of our investors.”

To compile the list, Inc. went straight to the source: entrepreneurs who have sold to private equity and venture capital firms. Founders filled out a questionnaire about their experiences partnering with private equity, venture capital, and debt firms and shared data on how their portfolio companies have grown during these partnerships.

“It has been a complicated few years for growth companies and the companies that fund them,” said Mike Hofman, editor-in-chief of Inc. “So, we are happy to share with our readers the best, latest guidance on which venture capital firms, private equity firms, and growth-capital lenders have the track record and reputation of being especially good partners to founders and CEOs.”

Introduced in 2019, the Founder-Friendly Investors list quickly established itself as one of Inc.’s most resourceful franchises. It has become a go-to guide for entrepreneurs who want to grow their companies while retaining an ownership stake.

More information about Inc.'s 2024 Founder-Friendly Investors list and a complete summary of firms recognized can be viewed here.

About Hildred Capital Management

Hildred Capital Management is a healthcare-focused private equity firm that seeks opportunities to create value in middle-market companies. The firm specializes in partnering with management teams to help them scale their platforms, generate earnings growth, promote strategic and operational improvements, generate business development, and drive multiple expansion. For more information, please visit www.hildredcapital.com and follow the Firm on LinkedIn.

About Inc.

Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of our community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating our future. Inc.'s award-winning work achieves a monthly brand footprint of more than 40 million across a variety of channels, including events, digital, print, video, podcasts, newsletters, and social media. Its proprietary Inc. 5000 list, produced every year since its launch as the Inc. 100 in 1982, analyzes company data to rank the fastest-growing privately held businesses in the United States. The recognition that comes with inclusion on this and other prestigious Inc. lists, such as Female Founders and Power Partners, gives the founders of top businesses the opportunity to engage with an exclusive community of their peers, and credibility that helps them drive sales and recruit talent. For more information, visit www.inc.com.

Contacts

Media Contact
Mike Geller
Mgeller@prosek.com

Hildred Capital Management


Release Versions

Contacts

Media Contact
Mike Geller
Mgeller@prosek.com

More News From Hildred Capital Management

Crown Laboratories Completes Acquisition of Revance Therapeutics

NEW YORK--(BUSINESS WIRE)--Yesterday, Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. Jeff Bedard, Founder and Chief Executive Officer of Crown commented, “We are excited to offici...

Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. Announce Exit from Pharmaceutics International, Inc.

NEW YORK--(BUSINESS WIRE)--A consortium of investors led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. today announced they have exited their equity stake in Pharmaceutics International, Inc. (“Pii”), a contract development and manufacturing organization, and have closed on an undisclosed all-cash transaction to sell the company to Jabil Inc. (NYSE: JBL), a global leader in engineering, manufacturing, and supply chain solutions. Pii is a cont...

Hildred Capital Announces Oversubscribed Final Close of Hildred Equity Partners III with Capital Commitments in Excess of $800 Million

NEW YORK--(BUSINESS WIRE)--Hildred Capital Management, LLC ("Hildred"), a lower middle-market healthcare private equity firm, today announced the successful final closing of its third fund, Hildred Equity Partners III (the “Fund”). The Fund was significantly oversubscribed, exceeding its $600 million target and hitting its hard cap in seven months. With total capital commitments in excess of $800 million, the Fund represents more than double the size of its predecessor fund, Hildred Equity Part...
Back to Newsroom